相似文献
1
The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature.
Br J Cancer. 2001 May 4;84(9):1150-5. doi: 10.1054/bjoc.2001.1742.
2
Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Cochrane Database Syst Rev. 2003(3):CD003231. doi: 10.1002/14651858.CD003231.
3
Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?
Br J Cancer. 2001 May 4;84(9):1143-5. doi: 10.1054/bjoc.2000.1740.
4
Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Anticancer Res. 2000 May-Jun;20(3B):1985-90.
5
Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells.
Biochem Pharmacol. 2016 Apr 1;105:91-100. doi: 10.1016/j.bcp.2016.02.016. Epub 2016 Feb 24.
6
The case for mitomycin in non-small cell lung cancer.
Oncology. 1993 Apr;50 Suppl 1:35-50. doi: 10.1159/000227246.
7
Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells.
Biochem Pharmacol. 2015 Oct 1;97(3):331-40. doi: 10.1016/j.bcp.2015.07.025. Epub 2015 Jul 23.
8
[Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Onkologie. 2005 Mar;28 Suppl 1:1-28. doi: 10.1159/000084364. Epub 2005 Mar 30.
9
Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study.
Lung Cancer. 2008 Sep;61(3):378-84. doi: 10.1016/j.lungcan.2008.01.011. Epub 2008 Mar 3.
10
A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Semin Oncol. 1994 Oct;21(5 Suppl 10):28-33; discussion 33-4.
引用本文的文献
1
New spiro-indeno[1,2-]quinoxalines clubbed with benzimidazole scaffold as CDK2 inhibitors for halting non-small cell lung cancer; stereoselective synthesis, molecular dynamics and structural insights.
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2281260. doi: 10.1080/14756366.2023.2281260. Epub 2023 Nov 23.
2
Novel NRF2-activated cancer treatments utilizing synthetic lethality.
IUBMB Life. 2022 Dec;74(12):1209-1231. doi: 10.1002/iub.2680. Epub 2022 Oct 18.
3
Overview of Ferroptosis and Synthetic Lethality Strategies.
Int J Mol Sci. 2021 Aug 27;22(17):9271. doi: 10.3390/ijms22179271.
4
NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer.
Mol Cell Biol. 2021 Jan 25;41(2). doi: 10.1128/MCB.00473-20.
5
Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages.
J Exp Clin Cancer Res. 2018 Oct 29;37(1):259. doi: 10.1186/s13046-018-0938-5.
6
Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
Pharm Res. 2018 Mar 13;35(5):96. doi: 10.1007/s11095-017-2337-6.
7
MicroRNA-128-3p regulates mitomycin C-induced DNA damage response in lung cancer cells through repressing .
Oncotarget. 2016 Sep 28;8(35):58098-58107. doi: 10.18632/oncotarget.12300. eCollection 2017 Aug 29.
8
Comments on a meta-analysis and systematic review of the clinicopathological significance of CDH1 in gastric cancer.
Drug Des Devel Ther. 2016 Mar 15;10:1159-60. doi: 10.2147/DDDT.S103922. eCollection 2016.
9
Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review.
Drug Des Devel Ther. 2015 Apr 15;9:2171-8. doi: 10.2147/DDDT.S78537. eCollection 2015.
10
The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review.
Drug Des Devel Ther. 2015 Apr 13;9:2149-57. doi: 10.2147/DDDT.S75429. eCollection 2015.
本文引用的文献
1
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.
Lung Cancer. 2000 Oct;30(1):23-36. doi: 10.1016/s0169-5002(00)00127-6.
2
Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
Anticancer Res. 1999 Sep-Oct;19(5C):4379-90.
3
A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer.
Respirology. 1996 Mar;1(1):49-54. doi: 10.1111/j.1440-1843.1996.tb00010.x.
4
Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study.
Lung Cancer. 1995 Aug;13(1):1-12. doi: 10.1016/0169-5002(95)00477-i.
5
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
J Clin Oncol. 1993 May;11(5):873-8. doi: 10.1200/JCO.1993.11.5.873.
6
Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.
Chest. 1994 Sep;106(3):861-5. doi: 10.1378/chest.106.3.861.
7
A method for assessing the quality of a randomized control trial.
Control Clin Trials. 1981 May;2(1):31-49. doi: 10.1016/0197-2456(81)90056-8.
8
Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
Cancer Treat Rep. 1981 Nov-Dec;65(11-12):965-72.
9
Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: a pilot study by the Lung Cancer Working Party (Belgium).
Cancer Treat Rep. 1986 Jun;70(6):773-5.
10
Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.
J Clin Oncol. 1986 Jul;4(7):1037-43. doi: 10.1200/JCO.1986.4.7.1037.
Zotero 插件